Is This Millionaire-Maker Biotech Stock a Buy Right Now?

If you had invested $20,000 in Vertex Pharmaceuticals (NASDAQ: VRTX) in its IPO in 1991 and held onto its shares, you'd have over $1 million today, considering the company's strong 14% compound annual growth rate since then, much better than the S&P 500's 11% over the same period. Maintaining this pace over more than three decades is commendable. However, can Vertex Pharmaceuticals still perform well from here on out? Image source: The Motley Fool.Vertex Pharmaceuticals has made quite a name for itself, given the company's dominance in its core market. It develops medicines for a rare disease called cystic fibrosis (CF), characterized by the accumulation of thick, sticky mucus in the lungs, which leads to a range of problems, including respiratory issues. Vertex Pharmaceuticals is the only notable player in this niche. Its portfolio of CF medicines has improved over time, enabling it to treat about 95% of CF patients in the U.S.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool